Across the board, these experts emphasized that the 2026 ASCO GU Cancer Symposium will provide patients and clinicians with ...
Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, will present new data ...
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced it will present new ...
Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative positron emission tomography (PET) radiopharmaceuticals, today announced that ...
Relay Therapeutics is approaching a pivotal clinical catalyst with the zovegalisib Phase 1/2 data readout at ESMO TAT. Check ...
We have a selection of films that give these beautiful, complex views of the Latino community and their stories,” said Consuelo Alba, Watsonville Film Festival executive director.
Day One Biopharmaceuticals, Inc. is rated Buy with net product revenues of $52.8M, up 36% from the prior quarter. Read more ...
The 2026 GU ASCO annual meeting featured a renal cell carcinoma session and a discussant presentation by Dr. Beckermann, discussing three abstracts, “Belzutifan + lenvatinib versus cabozantinib for ...
(UroToday.com) The 2026 GU ASCO annual meeting featured a kidney cancer trials in progress session and a presentation by Dr. Laurence Albiges discussing REJOICE-PanTumor01, a phase 2 signal-seeking ...
Adjuvant therapy with Imfinzi (durvalumab) and Imjudo (tremelimumab-actl) in patients with resected renal cell carcinoma was ...
In mCRPC patients with androgen receptor (AR) mutations, treatment with MRT-2359 in combination with enzalutamide led to a 100% PSA response rate (5 of 5 patients) and a 100% disease control rate, ...
MedPage Today on MSN
'Very Impressive' Survival With Combo in First-Line Prostate Cancer Study
Median overall survival with olaparib plus abiraterone reached 68 months in mid-stage tria ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results